modafinil has been researched along with Adverse Drug Event in 9 studies
Modafinil: A benzhydryl acetamide compound, central nervous system stimulant, and CYP3A4 inducing agent that is used in the treatment of NARCOLEPSY and SLEEP WAKE DISORDERS.
modafinil : A racemate comprising equimolar amounts of armodafinil and (S)-modafinil. A central nervous system stimulant, it is used for the treatment of sleeping disorders such as narcolepsy, obstructive sleep apnoea, and shift-work sleep disorder. The optical enantiomers of modafinil have similar pharmacological actions in animals.
2-[(diphenylmethyl)sulfinyl]acetamide : A sulfoxide that is dimethylsulfoxide in which two hydrogens attached to one of the methyl groups are replaced by phenyl groups, while one hydrogen attached to the other methyl group is replaced by a carbamoyl (aminocarbonyl) group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Methylphenidate, modafinil, and amantadine are commonly prescribed medications for alleviating fatigue in multiple sclerosis; however, the evidence supporting their efficacy is sparse and conflicting." | 9.41 | Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial. ( Aljarallah, S; Auvray, C; Cordano, C; Creasman, J; Jin, C; Krysko, K; Manguinao, M; McCulloch, C; Morris, B; Mowry, E; Nourbakhsh, B; Revirajan, N; Rutatangwa, A; Waubant, E, 2021) |
| "This double-blind study evaluated the efficacy and safety of modafinil for treating excessive daytime sleepiness in Japanese patients with obstructive sleep apnea syndrome (OSAS)." | 9.17 | Efficacy and safety of adjunctive modafinil treatment on residual excessive daytime sleepiness among nasal continuous positive airway pressure-treated japanese patients with obstructive sleep apnea syndrome: a double-blind placebo-controlled study. ( Inoue, Y; Takasaki, Y; Yamashiro, Y, 2013) |
| "Methylphenidate, modafinil, and amantadine are commonly prescribed medications for alleviating fatigue in multiple sclerosis; however, the evidence supporting their efficacy is sparse and conflicting." | 5.41 | Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial. ( Aljarallah, S; Auvray, C; Cordano, C; Creasman, J; Jin, C; Krysko, K; Manguinao, M; McCulloch, C; Morris, B; Mowry, E; Nourbakhsh, B; Revirajan, N; Rutatangwa, A; Waubant, E, 2021) |
| "This double-blind study evaluated the efficacy and safety of modafinil for treating excessive daytime sleepiness in Japanese patients with obstructive sleep apnea syndrome (OSAS)." | 5.17 | Efficacy and safety of adjunctive modafinil treatment on residual excessive daytime sleepiness among nasal continuous positive airway pressure-treated japanese patients with obstructive sleep apnea syndrome: a double-blind placebo-controlled study. ( Inoue, Y; Takasaki, Y; Yamashiro, Y, 2013) |
| "The primary objective of this open-label pilot study was to evaluate the safety, and efficacy of modafinil in improving cancer-related fatigue (CRF) as measured by the Brief Fatigue Inventory (BFI)." | 5.14 | A pilot study evaluating the safety and efficacy of modafinal for cancer-related fatigue. ( Baum, L; Blackhall, L; Farace, E; Petroni, G; Shu, J, 2009) |
| "Sodium oxybate (SXB) is an approved drug for the treatment of excessive daytime sleepiness (EDS) and cataplexy in narcolepsy." | 5.14 | A safety trial of sodium oxybate in patients with obstructive sleep apnea: Acute effects on sleep-disordered breathing. ( Feldman, N; George, CF; Grzeschik, SM; Inhaber, N; Lai, C; Steininger, TL; Zheng, Y, 2010) |
| "Modafinil was associated with DAAD in the total dataset (ROR, 2." | 1.46 | Sensitivity of Quantitative Signal Detection in Regards to Pharmacological Neuroenhancement. ( Connemann, BJ; Gahr, M; Schönfeldt-Lecuona, C; Zeiss, R, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 3 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, Z | 1 |
| Shi, Q | 1 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Fang, H | 1 |
| Tong, W | 1 |
| Sakatis, MZ | 1 |
| Reese, MJ | 1 |
| Harrell, AW | 1 |
| Taylor, MA | 1 |
| Baines, IA | 1 |
| Chen, L | 1 |
| Bloomer, JC | 1 |
| Yang, EY | 1 |
| Ellens, HM | 1 |
| Ambroso, JL | 1 |
| Lovatt, CA | 1 |
| Ayrton, AD | 1 |
| Clarke, SE | 1 |
| Heller, MK | 1 |
| Chapman, SCE | 1 |
| Horne, R | 1 |
| Elliott, J | 1 |
| Johnston, A | 1 |
| Husereau, D | 1 |
| Kelly, SE | 1 |
| Eagles, C | 1 |
| Charach, A | 1 |
| Hsieh, SC | 1 |
| Bai, Z | 1 |
| Hossain, A | 1 |
| Skidmore, B | 1 |
| Tsakonas, E | 1 |
| Chojecki, D | 1 |
| Mamdani, M | 1 |
| Wells, GA | 1 |
| Nourbakhsh, B | 1 |
| Revirajan, N | 1 |
| Morris, B | 1 |
| Cordano, C | 1 |
| Creasman, J | 1 |
| Manguinao, M | 1 |
| Krysko, K | 1 |
| Rutatangwa, A | 1 |
| Auvray, C | 1 |
| Aljarallah, S | 1 |
| Jin, C | 1 |
| Mowry, E | 1 |
| McCulloch, C | 1 |
| Waubant, E | 1 |
| Inoue, Y | 1 |
| Takasaki, Y | 1 |
| Yamashiro, Y | 1 |
| Gahr, M | 1 |
| Connemann, BJ | 1 |
| Schönfeldt-Lecuona, C | 1 |
| Zeiss, R | 1 |
| Blackhall, L | 1 |
| Petroni, G | 1 |
| Shu, J | 1 |
| Baum, L | 1 |
| Farace, E | 1 |
| George, CF | 1 |
| Feldman, N | 1 |
| Inhaber, N | 1 |
| Steininger, TL | 1 |
| Grzeschik, SM | 1 |
| Lai, C | 1 |
| Zheng, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis[NCT03185065] | Phase 3 | 141 participants (Actual) | Interventional | 2017-10-04 | Completed | ||
| A PILOT STUDY OF INTRAVENOUS, SUBANESTHETIC DOSE OF KETAMINE VS PLACEBO, A CROSSOVER DESIGN, FOR MULTIPLE SCLEROSIS RELATED FATIGUE[NCT06064162] | Early Phase 1 | 20 participants (Anticipated) | Interventional | 2023-10-31 | Not yet recruiting | ||
| Randomized Controlled Study to Evaluate the Effects of Modafinil in Cancer Related Fatigue in Patients Undergoing Radiation Therapy[NCT01440621] | Phase 3 | 217 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Participants will answer yes or no to this question: Taken into consideration the possible benefits and/or disadvantages of this medication, would you choose it, going forward to treat your MS fatigue?. The number of participants who answered Yes to this question is reported here." (NCT03185065)
Timeframe: Week 5 of each treatment period
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 39 |
| Amantadine | 41 |
| Modafinil | 55 |
| Methylphenidate | 55 |
ESS score during the fifth week of treatment period. The ESS score can range from 0 to 24. The higher the score, the higher that person's average sleep propensity in daily life, or their 'daytime sleepiness'. (NCT03185065)
Timeframe: Week 5 of each treatment period
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Placebo | 9.4 |
| Amantadine | 9.3 |
| Modafinil | 8.3 |
| Methylphenidate | 8.8 |
MFIS score during the fifth week of treatment period. The total score of the MFIS ranges from 0 to 84. Higher scores denote more severe fatigue. (NCT03185065)
Timeframe: Week 5 of each treatment period
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Placebo | 40.6 |
| Amantadine | 41.3 |
| Modafinil | 39.0 |
| Methylphenidate | 38.6 |
Neuro-QoL Item Bank - Fatigue T score during the fifth week of treatment period. T-score distributions rescale raw scores into standardized scores with a mean of 50 and a standard deviation (SD) of 10. Higher T-scores denote more severe fatigue. (NCT03185065)
Timeframe: Week 5 of each treatment period
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Placebo | 53.1 |
| Amantadine | 53.0 |
| Modafinil | 52.5 |
| Methylphenidate | 52.0 |
1 review available for modafinil and Adverse Drug Event
| Article | Year |
|---|---|
Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis.
Topics: Adult; Amphetamine; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Bayes | 2020 |
5 trials available for modafinil and Adverse Drug Event
| Article | Year |
|---|---|
Beliefs About Medicines Predict Side-Effects of Placebo Modafinil.
Topics: Cognition; Drug-Related Side Effects and Adverse Reactions; Humans; Modafinil; Nocebo Effect; Pharma | 2022 |
Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial.
Topics: Adult; Amantadine; Central Nervous System Stimulants; Cross-Over Studies; Double-Blind Method; Drug | 2021 |
Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial.
Topics: Adult; Amantadine; Central Nervous System Stimulants; Cross-Over Studies; Double-Blind Method; Drug | 2021 |
Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial.
Topics: Adult; Amantadine; Central Nervous System Stimulants; Cross-Over Studies; Double-Blind Method; Drug | 2021 |
Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial.
Topics: Adult; Amantadine; Central Nervous System Stimulants; Cross-Over Studies; Double-Blind Method; Drug | 2021 |
Efficacy and safety of adjunctive modafinil treatment on residual excessive daytime sleepiness among nasal continuous positive airway pressure-treated japanese patients with obstructive sleep apnea syndrome: a double-blind placebo-controlled study.
Topics: Adult; Aged; Benzhydryl Compounds; Combined Modality Therapy; Continuous Positive Airway Pressure; D | 2013 |
A pilot study evaluating the safety and efficacy of modafinal for cancer-related fatigue.
Topics: Activities of Daily Living; Affect; Benzhydryl Compounds; Central Nervous System Stimulants; Drug-Re | 2009 |
A safety trial of sodium oxybate in patients with obstructive sleep apnea: Acute effects on sleep-disordered breathing.
Topics: Adjuvants, Anesthesia; Adult; Aged; Benzhydryl Compounds; Central Nervous System Stimulants; Comorbi | 2010 |
3 other studies available for modafinil and Adverse Drug Event
| Article | Year |
|---|---|
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme | 2012 |
Sensitivity of Quantitative Signal Detection in Regards to Pharmacological Neuroenhancement.
Topics: Adrenergic Uptake Inhibitors; Adverse Drug Reaction Reporting Systems; Atomoxetine Hydrochloride; Au | 2017 |